Cancer Family
Basal Cell Neoplasm
CI-CAN-00000072Explore in graph →
Non-malignant58 active trials4 approved drugs6 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000072Explore in graph →
Clinical trials
362 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06398418 | R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors | recruiting | Phase 1 | 33 | Rise Therapeutics LLCINDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT05896839 | Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer | recruiting | Phase 1 / Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | Aug 31, 2026 |
| clinicaltrials |
| NCT05859074 | A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer | recruiting | Phase 1 | 56 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07600476 | A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors | recruiting | Phase 1 | 21 | Kupando GmbHINDUSTRY | 1 | Aug 12, 2026 | clinicaltrials |
| NCT03816332 | Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers | active not recruiting | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07670858 | Study of Intralesional FLD-103 in Subjects With Basal Cell Carcinoma (BCC) | recruiting | Phase 1 | 48 | Feldan TherapeuticsINDUSTRY | 2 | Jun 29, 2026 | clinicaltrials |
| NCT04616248 | In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors | active not recruiting | Phase 1 | 14 | University of Southern CaliforniaOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT06483555 | Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel(PANGEA) | recruiting | Phase 1 / Phase 2 | 104 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT04349436 | Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies(ARTACUS) | active not recruiting | Phase 1 / Phase 2 | 69 | Replimune, Inc.INDUSTRY | 1 | Apr 22, 2026 | clinicaltrials |
| NCT03646188 | Dose Escalation Trial to Evaluate Dose Limiting Toxicity/Maximum Tolerated Dose of Microneedle Arrays Containing Doxorubicin (D-MNA) in Basal Cell Carcinoma (BCC) | terminated | Phase 1 | 13 | SkinJect, Inc.INDUSTRY | 1 | Apr 16, 2026 | clinicaltrials |
| NCT06623201 | Blue-Light Photodynamic Therapy and Sonidegib for Multiple Basal Cell Carcinomas | recruiting | Phase 1 | 20 | Nathalie ZeitouniOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT03889912 | Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma | completed | Phase 1 | 97 | Regeneron PharmaceuticalsINDUSTRY | 3 | Jan 21, 2026 | clinicaltrials |
| NCT07251413 | Cemiplimab Plus Imiquimod and Laser Therapy As Neoadjuvant Treatment In Cutaneous Basal Cell Carcinoma(CEMIQUID) | recruiting | Phase 1 / Phase 2 | 18 | Instituto Oncológico Dr RosellOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT04272034 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors | terminated | Phase 1 | 105 | Incyte CorporationINDUSTRY | 7 | Oct 16, 2025 | clinicaltrials |
| NCT07010692 | Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin Ointment | recruiting | Phase 1 / Phase 2 | 100 | Bruce Robinson, MDOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT03897036 | Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC) | completed | Phase 1 | 25 | Senhwa Biosciences, Inc.INDUSTRY | 1 | May 20, 2025 | clinicaltrials |
| NCT00604890 | Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma | completed | Phase 1 / Phase 2 | 186 | BPGbioINDUSTRY | 1 | Feb 28, 2025 | clinicaltrials |
| NCT04470726 | Safety and Efficacy Evaluation of AIV001 in Nonmelanoma Skin Cancer of the Low Risk Basal Cell Carcinoma Subtype(NMSC) | completed | Phase 1 / Phase 2 | 26 | AiViva BioPharma, Inc.INDUSTRY | 1 | Dec 27, 2024 | clinicaltrials |
| NCT03467789 | Vitamin D as a Nutritional Neoadjuvant During Photodynamic Therapy of Basal Cell Carcinoma | completed | Phase 1 | 37 | Case Comprehensive Cancer CenterOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT04925713 | IFx-Hu2.0 for the Treatment of Patients With Skin Cancer | completed | Phase 1 | 5 | TuHURA Biosciences, Inc.INDUSTRY | 1 | Aug 2, 2024 | clinicaltrials |
| NCT04410874 | Imvamune Vaccine for the Treatment of Non-melanoma Skin Cancer(MUSIC-01) | terminated | Phase 1 / Phase 2 | 1 | Ivan LitvinovOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT05077033 | Intratumoral phIL12 GET(SmartGeneH&N) | completed | Phase 1 | 9 | Institute of Oncology LjubljanaOTHER | 1 | Dec 14, 2023 | clinicaltrials |
| NCT03982212 | A Window of Opportunity Trial of Intratumoral Injection of Copaxone® in Patients With Percutaneously Accessible Tumors | unknown | Phase 1 | 10 | University of Kansas Medical CenterOTHER | 1 | May 19, 2023 | clinicaltrials |
| NCT04928222 | Placebo Microneedles in Healthy Volunteers (Part I) and Efficacy/Safety of Doxorubicin Microneedles in Basal Cell Cancer Subjects (Part II) | active not recruiting | Phase 1 / Phase 2 | 25 | SkinJect, Inc.INDUSTRY | 1 | Apr 14, 2023 | clinicaltrials |
| NCT03775525 | Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer(GEN602) | unknown | Phase 1 | 127 | Genzada Pharmaceuticals USA, Inc.INDUSTRY | 1 | Dec 23, 2022 | clinicaltrials |
| NCT03517488 | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors(DUET-2) | completed | Phase 1 | 150 | Xencor, Inc.INDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT00470496 | Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer | completed | Phase 1 | 15 | Roswell Park Cancer InstituteOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT03541252 | Topical Laser-assisted Combination Chemotherapy for Basal Cell Carcinoma- a Clinical Study | completed | Phase 1 / Phase 2 | 20 | Merete HaedersdalOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT03458117 | T-VEC in Non-melanoma Skin Cancer(20139157 T-VEC) | completed | Phase 1 | 26 | University of ZurichOTHER | 1 | Mar 18, 2022 | clinicaltrials |
| NCT05157763 | A Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell Carcinoma | recruiting | Phase 1 / Phase 2 | 32 | MediWound LtdINDUSTRY | 1 | Dec 15, 2021 | clinicaltrials |
| NCT00880308 | Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors | completed | Phase 1 | 103 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 19, 2020 | clinicaltrials |
| NCT01208831 | An East Asian Study of LDE225 | completed | Phase 1 | 45 | Novartis PharmaceuticalsINDUSTRY | 3 | Dec 19, 2020 | clinicaltrials |
| NCT03734913 | A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors | unknown | Phase 1 | 65 | Guangdong Zhongsheng Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 22, 2020 | clinicaltrials |
| NCT01806675 | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy | completed | Phase 1 / Phase 2 | 25 | Sanjiv Sam GambhirOTHER | 1 | Oct 3, 2019 | clinicaltrials |
| NCT02367547 | Superficial Basal Cell Cancer's Photodynamic Therapy: Comparing Three Photosensitizers: HAL and BF-200 ALA Versus MAL | unknown | Phase 1 / Phase 2 | 117 | Joint Authority for Päijät-Häme Social and Health CareOTHER | 1 | Mar 28, 2019 | clinicaltrials |
| NCT02690948 | Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer | completed | Phase 1 / Phase 2 | 16 | Anne ChangOTHER | 1 | Mar 8, 2019 | clinicaltrials |
| NCT02639117 | Photodynamic Therapy and Vismodegib for Multiple Basal Cell Carcinomas(PDT-Vismo) | completed | Phase 1 | 4 | University of ArizonaOTHER | 1 | Jul 18, 2018 | clinicaltrials |
| NCT03569345 | Basal Cell Carcinomas Treated With Ablative Fractional Laser and Ingenol Mebutate | completed | Phase 1 / Phase 2 | 20 | Merete HaedersdalOTHER | 1 | Jul 10, 2018 | clinicaltrials |
| NCT01791894 | Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma(ATO) | completed | Phase 1 / Phase 2 | 5 | Stanford UniversityOTHER | 1 | Jun 8, 2018 | clinicaltrials |
| NCT02550678 | A Study of the Efficacy and Safety of ASN-002 in Adult Patients With Low-risk Nodular Basal Cell Carcinoma(ASN-002-001) | completed | Phase 1 / Phase 2 | 16 | Ascend Biopharmaceuticals LtdINDUSTRY | 1 | Jun 6, 2018 | clinicaltrials |
| NCT01808950 | Efficacy and Safety Trial of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma | terminated | Phase 1 / Phase 2 | 4 | Spirig Pharma Ltd.INDUSTRY | 2 | Jun 22, 2016 | clinicaltrials |
| NCT02059252 | Safety, Tolerability and Performance of SmartMatrix Dermal Replacement Scaffold | terminated | Phase 1 / Phase 2 | 5 | Smart Matrix LimitedOTHER | 1 | Apr 4, 2016 | clinicaltrials |
| NCT00397384 | Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer | completed | Phase 1 | 43 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2015 | clinicaltrials |
| NCT01292668 | Photodynamic Therapy Using Methyl-5-Aminolevulinate Hydrochloride Cream in Determining Pain Threshold in Patients With Skin Cancer | completed | Phase 1 | 21 | Roswell Park Cancer InstituteOTHER | 1 | Sep 29, 2014 | clinicaltrials |
| NCT00670189 | A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer | completed | Phase 1 | 53 | Bristol-Myers SquibbINDUSTRY | 2 | Aug 15, 2014 | clinicaltrials |
| NCT00101348 | Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Jun 11, 2014 | clinicaltrials |
| NCT02018679 | Er:YAG Ablative Fractional Laser Assisted-Photodynamic Therapy Versus Photodynamic Therapy for Basal Cell Carcinoma | completed | Phase 1 | 34 | Dong-A UniversityOTHER | 1 | Dec 23, 2013 | clinicaltrials |
| NCT00391300 | Bioelectric Field Imaging in Diagnosing Melanoma and Other Skin Cancers in Patients With Skin Lesions | unknown | Phase 1 | 100 | Eastern Virginia Medical SchoolOTHER | 1 | Dec 18, 2013 | clinicaltrials |
| NCT00031681 | 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) | completed | Phase 1 | 41 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
Data updated 11 days agoSource updated Sep 18, 2026source: clinicaltrials